Barbosa-Júnior FV, Sanchez-Lermen RLP, Vieira KA, de Oliveira RV, Souto FJD

Language: English
References: 21
Page: 470-476
PDF size: 113.08 Kb.

ABSTRACT

Background and rationale for the study. Hepatitis B virus (HBV) chronic infection may follow a benign course with low risk of cirrhosis or liver cancer. As differentiation of inactive status from HBeAg-negative chronic hepatitis B is often challenging, monitoring of inactive HBV carriers is important to detect viral relapse or formerly undetected activity. The incidence of hepatitis activity in HBeAg-negative carriers with normal aminotransferases was examined by retrospective analysis of a cohort of carriers who had been followed- up at a hospital in Central Brazil. All patients had remained free of evidence of liver disease and maintained normal aminotransferase levels throughout the first year of follow-up. The incidence density of chronic HBV activity was determined and an incidence curve was constructed using the Kaplan-Meier method. Cox regression models were developed to identify for surrogate markers of activity. Results. Among the 224 patients who comprised the cohort, chronic HBV activity was detected in 30 during followup. The incidence density of activity was 11.8 per 100 person-years (95% confidence interval: 8.3-16.9). The results of Cox regression analysis indicated that chronic HBV activity was associated with entrance in the latter years of the period examined (p = 0.001) and initial normal aspartate aminotransferase (AST) levels close to the upper-normal value (p = 0.022). Conclusion. Normal AST levels near the upper-normal value may be an indicator of relapse or previously undetected activity, and should thus be monitored closely in HBeAg-negative HBV carriers, in whom risk of relapse should remain an important managing consideration.

REFERENCES

1. Raptopoulou M, Papatheodoridis G, Antoniou A, Ketikoglou J, Tzourmakliotis D, Vasiliadis T, Manolaki N, et al. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET Study for Chronic Hepatitis B: a multicentre Greek study. J Viral Hepat 2009; 16: 195-202.

2. Ganem D, Prince AM. Mechanism of disease: hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

3. Fattovich G, Olivari N, Pasino M. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.

4. Hadziyannis SJ. Unrevealing the natural course of the socalled “inactive HBsAg or HBV carrier state”. Hepatol Int 2007; 1: 281-4.

5. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.

6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 30: 1-36.

7. Manno M, Cammŕ C, Schepis F, Bassi F, Gelmini R, Giannini F, Miselli F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-63.

8. Chen JD, Yang HI, Uchenna HI, You SL, Lu SN, Wang LY, Su J, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Gastroenterology 2010; 138: 1747-54.

9. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis 2007; 27: 3-8.

10. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61.

11. Galizzi-Filho J, Teixeira R, Fonseca JC, Souto FJ. Clinical profile of hepatitis B virus chronic infection in patients of Brazilian liver reference units. Hepatol Int 2010; 4: 511-5.

12. McMahon BJ. The natural history of chronic hepatitis B virus Infection. Hepatology 2009; 49: 45-54.

13. European Association for the Study of Liver Disease. EASL clinical practical guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.

14. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34: 139-42.

15. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.

16. Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou- Gigi M. Long term follow-up of a large cohort of inactive HBsAg (+)/HBeAg (-)/ anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis 2009; 16: 19-22.

17. Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers from Taiwan. Hepatol Int 2007; 1: 311-5.

18. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57: 196-202.

19. Martinot-Peignoux M, Boyer N, Colombat M. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543-6.

20. Berk P, Korenblat K. Approach to the patient with jaundice or abnormal liver tests. In: Goldman L, Schafer A (eds.). Cecil Medicine, 24th Ed. Philadelphia: Elsevier- Saunders; 2012, p. 956-66.

21. Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol 2009; 50: 1065-9.